The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.